GRFS Grifols
WatchlistGrifols News
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday
European equities traded in the US as American depositary receipts were trending modestly higher Wednesday, rising 0.43% to 1,234.16 on the S&P Europe Select ADR Index. From continental Europe, the ga
Kepler Capital Keeps Their Buy Rating on Grifols SA (GRFS)
JP Morgan Maintains Neutral on Grifols, Raises Price Target to $10.5
JP Morgan analyst James Quigley maintains Grifols (NASDAQ:GRFS) with a Neutral and raises the price target from $10 to $10.5.
Grifols Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/05/2023 7.14% JP Morgan $10 → $10.5 Maintains Neutral 11/05/2021 — Deutsche Bank Downgrades Buy → Hold
Kepler Capital Remains a Buy on Grifols SA (GRFS)
Grifols Completes Cohort 1 In Clinical Study Of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option For Patients With Alpha1-Antitrypsin Deficiency
Study designed to demonstrate impact of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), an alpha1 antitrypsin treatment, compared with Liquid Alpha1-Proteinase Inhibitor (Human) in
Travel, Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday
Travel and pharma stocks led European equities traded in the US as American depositary receipts sharply higher Tuesday, rising 1.36% to 1,212.96 on the S&P Europe Select ADR Index. From continental Eu
Blood Screening (Reagent & Kits, Instrument, Software) Market - Global Forecast to 2028 Featuring F. Hoffmann-La Roche, Grifols, Abbott Laboratories, Bio-Rad Laboratories, Danaher, and BioMerieux
GigaGen, A Subsidiary Of Grifols Presents IND-Enabling Data And Phase 1 Trial Strategy For Its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, At SITC 2023
Researchers from the National Cancer Institute will conduct the Phase 1 trial, as established in a recently signed Cooperative Research and Development Agreement (CRADA) GigaGen anticipates tri
Kepler Capital Sticks to Their Buy Rating for Grifols SA (GRFS)
Invest Securities Trims Grifols PT, Maintains Buy Rating
Invest Securities on Friday decreased its price target on Grifols (GRF.MC) to 18.00 euros from 19.00 euros and maintained a buy recommendation. The Spanish pharmaceutical group was up almost 1% on Fri
Top Gap Ups and Downs on Thursday: SBUX, SHOP, PLTR and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
European Equities Traded in the US as American Depositary Receipts Sharply Higher Thursday
European equities traded in the US as American depositary receipts were sharply higher Thursday, rising 1.94% to 1,192.13 on the S&P Europe Select ADR Index. From continental Europe, the gainers were
Grifols S.A. Reports Q3 Results
Bloodbuy Announces Agreement With Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on Its Digital Marketplace
Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an
Grifols S.A. Q3 2023 Earnings Preview
European Equities Traded in the US as American Depositary Receipts Rebound Wednesday After Slow Start
European equities traded in the US as American depositary receipts were rebounding Wednesday morning after starting the session in negative territory, rising 0.26% to 1,179.00 on the S&P Europe Select
Express News | Grifols' Araclon Biotech Announces Final Results From Its Phase 2 Trial Of ABvac40, An Active Vaccine Against The Aβ40 Peptide, For The Treatment Of Patients With Early-Stage Alzheimer's Disease
Araclon Biotech Presents Positive Final Results From Phase 2 Clinical Study of ABvac40 Alzheimer's Vaccine at CTAD
Araclon Biotech today announced encouraging final results from its Phase 2 trial (NCT03461276) of ABvac40, an active vaccine against the Aβ40 peptide, for the treatment of patients with early-stage Alzheimer's disease (AD).
AIS Healthcare's Advanced Infusion Care Announces Joint Study With Grifols to Continue Improving Patient Care
Study to observe effects of subcutaneous immunoglobulin therapy on individuals living with primary immune deficiencies Advanced Infusion Care (AIC), a division of AIS Healthcare, today announced an agreement to